Dr. Jocelyn Gravel, MD
Claim this profileCHU Sainte-Justine
Affiliated Hospitals
CHU Sainte-Justine
Sainte-Justine Hospital
Clinical Trials Jocelyn Gravel, MD is currently running
Amoxicillin
for Pneumonia
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).
Recruiting
1 award
Phase 2 & 3
5 criteria
Magnesium
for Asthma
Despite optimal initial emergency department (ED) therapy, 50% of children with severe acute asthma have ongoing moderate-severe respiratory distress. Guidelines recommend intravenous magnesium (IVMg) for them, yet evidence for IVMg efficacy is scant and disparate. While early small Randomized Controlled Trials (RCTs) suggested hospitalization benefit, recent large observational studies found no association between IVMg and improved outcomes. IVMg therapy is resource-intensive, can cause hypotension and demands close monitoring. Previous RCTs only assessed early Mg effect at 1-2 hours, overlooked the peak effect of key co-interventions such as corticosteroids and did not use validated scores. IVMg use is variable and often delayed until ≥4 hours after ED therapy is started and after the hospitalization decision has been made. Thus, in observational studies children given IVMg are 6-10 times more likely to be hospitalized; these studies have major confounding and the true IVMg treatment effect is thus unknown. To conclusively determine if IVMg alters the exacerbation course, it must be given early, and the primary outcome measure should be the severity of respiratory distress measured at the peak effect of key co-interventions to focus on a clinically meaningful and objective effect. The Pediatric Respiratory Assessment Measure (PRAM)-a valid, discriminative, reproducible and responsive-to-change instrument-is thus the ideal primary outcome measure. Hospitalization outcome has major confounding by indication and MD perceptions. Primary Aim: In children with acute asthma remaining in moderate-severe distress after 1 hour of initial ED therapy, is early IVMg therapy associated with a significantly greater improvement in respiratory distress, measured by PRAM, at 2 hours after starting the intervention, compared to placebo? Hypothesis: IVMg will yield significantly greater PRAM improvement of ≥1.0 point than placebo. Expected Outcomes: This trial will clarify if there is an incremental benefit of IVMg in decreasing respiratory distress in pediatric refractory acute asthma. A positive result will establish a proven standard of care for this indication, with a need for Knowledge Translation (KT) to implement routine early IVMg therapy. A negative result will lead to de-implementation of IVMg which may also lead to cost savings.
Recruiting
1 award
Phase 3
3 criteria
More about Jocelyn Gravel, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 7 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jocelyn Gravel, MD has experience with
- Sucrose
- Amoxicillin
- Valacyclovir
- Placebo
- Magnesium Sulfate
- Placebo Group
Breakdown of trials Jocelyn Gravel, MD has run
Unexplained Vomiting
Community-acquired Pneumonia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jocelyn Gravel, MD specialize in?
Jocelyn Gravel, MD focuses on Unexplained Vomiting and Emergency. In particular, much of their work with Unexplained Vomiting has involved treating patients, or patients who are undergoing treatment.
Is Jocelyn Gravel, MD currently recruiting for clinical trials?
Yes, Jocelyn Gravel, MD is currently recruiting for 2 clinical trials in Montreal Quebec. If you're interested in participating, you should apply.
Are there any treatments that Jocelyn Gravel, MD has studied deeply?
Yes, Jocelyn Gravel, MD has studied treatments such as Sucrose, Amoxicillin, Valacyclovir.
What is the best way to schedule an appointment with Jocelyn Gravel, MD?
Apply for one of the trials that Jocelyn Gravel, MD is conducting.
What is the office address of Jocelyn Gravel, MD?
The office of Jocelyn Gravel, MD is located at: CHU Sainte-Justine, Montreal, Quebec H3T1C5 Canada. This is the address for their practice at the CHU Sainte-Justine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.